Research
Radiobiology and Targeted Radiotherapy : Jean-Pierre POUGET & David AZRIA

activities

Our team is studying the biological response of the tumor and its microenvironment to targeted radionuclide therapy used alone or in combination with external radiotherapy, chemotherapy, or immunotherapy.

More

Publications

MHC-I-driven anti-tumor immunity counterbalances low absorbed doses of targeted radionuclide therapy. J Nucl Med. 2025 (in press).

Kayal G, Barbosa N, Marín C, Ferrer L, Fragoso-Negrín J-A, Grosev D, Gupta S, Hidayati N, Moalosi T, Poli G, Thakral P, Tsapaki V, Vauclin S, Vergara-Gil A, Knoll P, Hobbs R, Bardičs M Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study. J Nucl Med. 2024;65(1):125-131. doi:10.2967/jnumed.122.265340

Poty S, Ordas L, Dekempeneer Y, Parach A, Navarro L, Santens F, Dumauthioz N, Bardičs M, Lahoutte T, D'Huyvetter M, Pouget J-P Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting. J Nucl Med. 2024;65(10):1564-1570. doi:10.2967/jnumed.124.267624

Pouget J-P, Chan T, Galluzzi L, Constanzo J Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors. Trends Cancer. 2023;9(11):968-981. doi:10.1016/j.trecan.2023.07.014

Idrissou M, Pichard A, Tee B, Kibedi T, Poty S, Pouget J-P Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide. Pharmaceutics. 2021;13(7):980. doi:10.3390/pharmaceutics13070980


Team

Team Leader  :  Jean-Pierre Pouget & David Azria

Institut de Recherche en
Cancérologie de Montpellier
Campus Val d’Aurelle
34298 Montpellier cedex 5

Tél. : 33 (0)4 11 28 31 78
jean-pierre.pouget@inserm.fr

Tél. : 33 (0)4 67 61 31 32
david.azria@icm.unicancer.fr

Partners / Funding


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés